Extranodal NK/T Cell Lymphoma, Nasal Type

  • Masahiko OguchiEmail author


The extended involved site radiation therapy (ISRT) is incorporated into the treatment of patients with stage I and contiguous stage II extranodal natural killer/T cell lymphoma. It is suggested combined modality therapy with radiation and chemotherapy. The extended ISRT should be given concurrently with chemotherapy, but if the patient’s performance status and comorbidities do not allow concurrent therapy, radiation should be administered prior to chemotherapy.


Nasal cavity Extranodal natural killer/T cell lymphoma Nasal type Extended involved site radiation therapy (extended ISRT) Epstein-Barr virus (EBV) 


  1. 1.
    Swerdlow SH, Campo E, Harris NL, editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.Google Scholar
  2. 2.
    Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood. 2011;118:6018.CrossRefPubMedGoogle Scholar
  3. 3.
    Kako S, Izutsu K, Ota Y, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol. 2007;18:1685.CrossRefPubMedGoogle Scholar
  4. 4.
    Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24:612.CrossRefPubMedGoogle Scholar
  5. 5.
    Suzuki R, Suzumiya J, Yamaguchi M, et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol. 2010;21:1032–40.CrossRefPubMedGoogle Scholar
  6. 6.
    Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after nonanthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016;17:389–400.CrossRefPubMedGoogle Scholar
  7. 7.
    Yang Y, Zhu Y, Cao JZ, et al. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study. Blood. 2015;126:1424–32.CrossRefPubMedGoogle Scholar
  8. 8.
    Yang Y, Zhang YJ, Zhu Y, et al. Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter study. Leukemia. 2015;29:1571–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009;27:5594.CrossRefPubMedGoogle Scholar
  10. 10.
    Yamaguchi M, Tobinai K, Oguchi M, et al. Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211. J Clin Oncol. 2012;30:4044.CrossRefPubMedGoogle Scholar
  11. 11.
    Yamaguchi M, Suzuki R, Oguchi M, et al. Treatments and outcomes of patients with extranodal natural killer/T-cell lymphoma diagnosed between 2000 and 2013: a Cooperative Study in Japan. J Clin Oncol. 2017;35:32.CrossRefPubMedGoogle Scholar
  12. 12.
    Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol. 2009;27:6027.CrossRefPubMedGoogle Scholar
  13. 13.
    Kim SJ, Yang DH, Kim JS, et al. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. Ann Hematol. 2014;93:1895.CrossRefPubMedGoogle Scholar
  14. 14.
    Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006;24:181.CrossRefPubMedGoogle Scholar
  15. 15.
    Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29:4410.CrossRefPubMedGoogle Scholar
  16. 16.
    Yahalom J, Illidge T, Specht L, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92:11.CrossRefPubMedGoogle Scholar
  17. 17.
    Isobe K, Uno T, Tamaru J, et al. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer. 2006;106:609.CrossRefPubMedGoogle Scholar
  18. 18.
    Sakata K, Fuwa N, Kodaira T, et al. Analyses of dose-response in radiotherapy for patients with mature T/NK-cell lymphomas according to the WHO classification. Radiother Oncol. 2006;79:179.CrossRefPubMedGoogle Scholar
  19. 19.
    Huang MJ, Jiang Y, Liu WP, et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys. 2008;70:166.CrossRefPubMedGoogle Scholar
  20. 20.
    Wang H, Li YX, Wang WH, et al. Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK/T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2012;82:1115.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan 2017

Authors and Affiliations

  1. 1.Radiation Oncology DepartmentThe Cancer Institute Hospital Japanese Foundation for Cancer ResearchTokyoJapan

Personalised recommendations